The European Commission has approved AVEO Oncology’s Fotivda (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma in the European Union plus Norway and Iceland.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
